Summary The investigational anti-tumour agent, 5,6-dimethylxanthenone-4-acetic acid (5,, an analogue of flavone acetic acid (FAA), has been scheduled for clinical evaluation. Like FAA, 5,6-MeXAA exhibits excellent experimental anti-tumour activity and is an efficient inducer of cytokines in mice. We have examined the effect of pharmacological suppression of tumour necrosis factor (TNF) production on the anti-tumour activity of 5,6-MeXAA, taking advantage of previous observations that TNF production in response to endotoxin in vitro is inhibited by thalidomide. Thalidomide at doses of between 8 and 250 mg kg-' efficiently suppressed serum TNF activity in response to 5,6-MeXAA at its optimal TNF inducing dose of 55 mg kg-'. Suppression was achieved when thalidomide was administered at the same time as, or up to 4 h before, 5,6-MeXAA. Under conditions in which TNF activity was suppressed, the degree of tumour haemorrhagic necrosis and the proportion of cures in the subcutaneous Colon 38 tumour were increased. In mice administered thalidomide (100 mg kg-') together with 5,6-MeXAA (30mg kg-1), complete tumour regression was obtained in 100% of mice, as compared with 67% in mice receiving 5,6-MeXAA alone. The results suggest a possible new application for thalidomide and pose new questions about the action of 5,6-MeXAA and related compounds.
The investigational anti-tumour agent, 5,6-dimethylxanthenone-4-acetic acid (5,6-MeXAA; see Figure 1 for structure), has been scheduled for clinical evaluation as a more potent analogue of the biological response modifier flavone acetic acid (FAA). Both 5,6-MeXAA and FAA exhibit excellent anti-tumour activity and are efficient inducers of cytokines in mice (Mace et al., 1990; Ching et al., 1994a; Philpott et al., 1995) . Antibodies to tumour necrosis factor (TNF) inhibit FAA-induced tumour vascular collapse (Mahadevan et al., 1990) , a critical early effect of the drug leading to tumour ischaemia and necrosis (Bibby et al., 1989; Zwi et al., 1989) . Treatment with antibodies to TNF also leads to a reduction in toxicity and in the anti-tumour action of FAA (Pratesi et al., 1990) . We have shown that within 2 h of administration serum TNF activity is elevated following treatment with 5,6-MeXAA or FAA but not with an inactive analogue, 8-methylxanthenone-4-acetic acid (8-MeXAA) (Philpott et al., 1995) . These studies suggest an important role for TNF in the anti-tumour effects of FAA. However, in contrast to these results, lipopolysaccharide (LPS) does not induce cures or significant tumour growth delays in mice with implanted Colon 38 tumours despite inducing serum TNF to higher levels than does 5,6-MeXAA at its optimal anti-tumour dose (Ching et al., 1994a) . Thus, the elevation of serum TNF is not solely responsible for the anti-tumour effects of 5,6-MeXAA, and other cytokines or immune functions must contribute to the cures and growth delays observed with this agent.
In this report, we have examined the effect of pharmacological suppression of TNF production on the anti-tumour activity of 5,6-MeXAA. We have taken advantage of the observation that thalidomide (structure in Figure 1 ) inhibits TNF production by human peripheral blood monocytes induced by LPS in vitro (Sampaio et al., 1991) . In contrast to other inhibitors such as dexamethasone, which suppress production of a spectrum of cytokines, thalidomide suppresses TNF production by selectively increasing the rate of degradation of TNF mRNA without affecting interleukin 1 (IL-1), granulocyte-macrophage colony-stimulating factor (GM-CSF) or IL-6 production (Moreira et al., 1993 until assay for TNF. TNF activity was measured using the standard L929 cytotoxicity assay as previously described (Hogan and Vogel, 1990) . Briefly, L929 cells (3 x 104 per well) were allowed to adhere overnight to the bottom of flat-bottomed microwells. Actinomycin D (final concentration 8 tLg ml-') was then added to the wells followed by serial dilutions of the serum to be assayed. Cell killing was assessed after 24 h by a colorimetric assay using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) as previously described (Finlay et al., 1986) . One unit of TNF was defined as that required to kill 50% of the L929 cells.
Assessment of haemorrhagic necrosis Tumour-bearing mice were injected intraperitoneally with drug. 5,6-MeXAA was administered in a volume of 0.01 ml per g body weight and thalidomide in a volume of 2.5 "tl per g body weight. The tumours were removed 24 h later, fixed in formalin (10%) and embedded in paraffin wax. Sections were stained with haematoxylin and eosin, examined on a grid marked at 0.4 mm intervals and scored for percentage necrosis as previously described . Haemorrhagic necrosis assays were carried out using tumours between 6 and 10 mm across in their widest diameter. Effect of thalidomide on serum TNF activity induced by 5,6-MeXAA Sera from individual (non-tumour-bearing) mice, treated 2 h previously with 5,6-MeXAA (55 mg kg-') either alone or together with thalidomide (100 mg kg-'), were assayed for TNF (Figure 2 ). The dose of 5,6-MeXAA was chosen because it induced the maximal TNF response, and although it was above the maximum tolerated dose in long-term experiments it caused no toxicity over the time of the assay (Philpott et al., 1995) . The (geometric) mean TNF activities in serum were 1960 units ml-' for mice given 5,6-MeXAA alone, 160 units ml-' for mice given 5,6-MeXAA plus thalidomide, 13 units ml-' in untreated control mice and 11 units ml-' in mice administered thalidomide only. Despite some scatter in the group receiving 5,6-MeXAA plus thalidomide, all of the determinations lay below the mean of the group which received 5,6-MeXAA only and a statistically significant suppression of 83% (P<0.001) was obtained. Subsequent experiments were carried out using TNF determinations from serum pooled from three mice per group. Inhibition of the response to 5,6-MeXAA was obtained following doses of thalidomide ranging from 8 to 250 mg kg-1 (Figure 3) . Inhibition was observed when thalidomide was given either at the same time as or up to 4 h before 5,6-MeXAA (Figure 4) . No suppression was obtained in mice pretreated with thalidomide 12 or 24 h before 5,6-MeXAA. Thalidomide on its own, or dimethyl sulphoxide (DMSO) in which it was dissolved, had no toxic effect on the mice or TNF activity (Figures 3 and 4) . The time course in the presence and absence of thalidomide, as shown in Figure 5 , indicates that thalidomide suppressed rather than delayed TNF production. long-term experiments as well as the optimal anti-tumour dose. Some mice were also given thalidomide (100mgkg-').
Three mice per group were tested for serum TNF activity after 2 h and the other five mice in each group were sacrificed after 24 h for assessment of tumour haemorrhagic necrosis. TNF activity induced by 5,6-MeXAA in tumour-bearing mice was similar to that obtained from age-and sex-matched non-tumour-bearing control mice, and was similarly inhibited by thalidomide (results not shown). However, suppression of 5,6-MeXAA-induced haemorrhagic necrosis was not observed following the same thalidomide treatment (Figure 6 ). Rather, the tumours from mice which had received both 5,6-MeXAA and thalidomide showed greater amounts of haemorrhagic necrosis than tumours treated with 5,6-MeXAA alone. The growth delays of Colon 38 tumours growing in mice treated with 5,6-MeXAA (30 mg kg-1) with or without thalidomide (100 mg kg-') are shown in Figure 7 . Two independent experiments were performed, and since the data were comparable they were combined. Mice treated with 5,6-MeXAA alone provided a mean tumour growth delay of 20 days and complete cures in 8/12 mice. Thalidomide alone provided a small growth delay and no cures. However, when thalidomide was administered together with 5,6-MeXAA, the anti-tumour response was greater than that of mice treated with 5,6-MeXAA alone (Figure 7 although thalidomide effectively inhibited 5,6-MeXAA-induced TNF activity in the serum of tumour-bearing mice, tumour haemorrhagic necrosis and cure rates were both enhanced.
Discussion
Thalidomide is an effective inhibitor of LPS-induced TNF production (Sampaio et al., 1991) , and we have shown here that thalidomide also inhibits TNF production in response to 5,6-MeXAA (Figures 2-5) . Thalidomide also enhances antitumour activity when administered in combination with 5,6-MeXAA (Figures 6 and 7) . This result was unexpected in view of other studies demonstrating that administration of antibodies to TNF inhibits tumour vascular collapse (Mahadevan et al., 1990 ) and anti-tumour effects (Pratesi et al., 1990) induced by FAA, an analogue of 5,6-MeXAA. Our results using thalidomide show that under conditions where systemic TNF activity has been suppressed, a vigorous antitumour response is still obtained, and could simplistically be interpreted as indicating that the anti-tumour effects induced by 5,6-MeXAA are not dependent on systemic TNF activity.
The source of the serum TNF is not clear. We have previously demonstrated up-regulation of TNF mRNA in mouse splenocytes treated with 5,6-MeXAA (Ching et al., 1994b) , but its contribution to TNF activity in the serum has not been established. The serum TNF might also be produced by blood monocytes or by the liver. It is also not known whether serum TNF levels reflect TNF activity within the tumour. Localised TNF production by tumour-associated macrophages may be more important than serum levels for the anti-tumour activity of 5,6-MeXAA, and may continue under conditions in which serum TNF production has been reduced. Studies on the effects of thalidomide on 5,6-MeXAA-induced TNF production in tumours are in progress.
Since thalidomide by itself has only a small effect on haemorrhagic necrosis ( Figure 6 ) and tumour growth ( Figure  7) , its ability to enhance the anti-tumour response of 5,6-MeXAA was unexpected. TNF is angiogenic (Folkman and Shing, 1992) , and endogenously produced TNF may be contributing to tumour growth by promoting tumour angiogenesis. Inhibition of TNF production by thalidomide might therefore lead to disruption of tumour angiogenesis. However, it is difficult to understand how a single dose of thalidomide could lead to long-term effects and cures. One possible explanation for the enhancement by thalidomide of the 5,6-MeXAA anti-tumour effect might be that it prevents the cleavage and release of TNF from the macrophages but not its production within the cell. Thus, while circulating TNF is decreased, a greater number of 'armed' macrophages expressing cell-surface TNF are able to act against tumour cells. The processing and cleavage of the TNF precursor to the mature TNF involves several matrix metalloproteinaselike enzymes, and metalloproteinase inhibitors have been shown to block TNF secretion (Gearing et al., 1994; McGeehan et al., 1994 ). The precise mechanism by which thalidomide blocks TNF production is not known, although it has been suggested that it is at the post-transcriptional stage, perhaps by acceleration of TNF mRNA degradation (Moreira et al., 1993) . It would be of interest to determine whether metalloproteinase inhibitors resemble thalidomide when administered in conjunction with 5,6-MeXAA.
Thalidomide was withdrawn from the market as a sedative agent in the 1960s because of its teratogenicity (Fabro et al., 1967) . However it is re-emerging as adjunct therapy for a variety of diseases, including AIDS, leprosy, graft vs host, cachexia associated with cancer, and other diseases which show an involvement of TNF (Ehninger et al., 1993; McCormick et al., 1994; Silva et al., 1994) . TNF is produced in mice in response to 5,6-MeXAA (Philpott et al., 1995) , and the haematological effects of the compound are more similar to those induced by TNF than to those induced by conventional anti-cancer agents (Ching et al., 1991) . The demonstration here that thalidomide suppresses systemic TNF activity and concomitantly enhances anti-tumour activity induced by 5,6-MeXAA suggests a possible new application for thalidomide. 5,6-MeXAA is scheduled for clinical evaluation in human malignancies and an understanding of the action of thalidomide will be important in developing strategies to opt-imise the anti-tumour response to this drug.
